List of Implants Companies in Germany - 10

aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ® and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it has a broad network of distributors in more than 20 countries at the international level. aap Implantate AG is a stock listed company. Its share is quoted in the General Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). .

Acousia is a pioneer of novel medicines. Founded in 2012, the company’s experienced and entrepreneurial management team is committed to combating hearing loss. Thanks to its exclusive collaboration agreement with the renowned Translational Hearing Research Group of Tuebingen University Clinic and an ecosystem of experts and CROs, Acousia has made significant strides with its advanced small molecule drug candidates.

Cardiac Dimensions is reimagining the solutions available to patients suffering from heart failure (HF) by providing a therapy which allows patients to live longer, higher quality lives. Our product, the Carillon Mitral Contour System®, is a groundbreaking, non-surgical device developed to treat patients with mitral valve insufficiency in a safe and effective manner. The Carillon therapy is the only indirect, no-touch mitral valve repair option designed to produce an annuloplasty effect while initiating left ventricular remodeling and improving long-term survival for patients. The Carillon therapy can also be used alongside other HF treatments should they be needed. Learn more about this proven solution for HF patients that uniquely treats the underlying causes—not symptoms—of mitral insufficiency at the website link below.

At Cellbricks, we are committed to make a significant impact on the lives of millions of patients dealing with compromised organ function. We achieve this through the innovative production of bioprinted tissue therapeutics, offering humans longer and healthier lives by restoring or supporting organ function. Cellbricks is a biotech company, combining world-leading expertise in synthetic biology and 3D-bioprinting. Leveraging our proprietary biofabrication technology and our tissue engineering proficiency, we are replicating human tissue at scale so researchers and doctors can provide patients with better clinical treatments. Our rapidly growing, multi-disciplinary team consists of biotech enthusiasts, scientists, PhDs, engineers, chemists and entrepreneurs from excellent universities and top companies from all over the world. Our labs and offices are located in Berlin, Europe's start-up capital. For inquiries please contact: Moritz Marschall mm@cellbricks.com

Heraeus is a family-owned global technology group headquartered in Hanau, Germany. The company's roots go back to a family pharmacy started in 1660. With its expertise and resources, Heraeus has been making meaningful contributions over generations and is committed to do so in the future. Today, the group bundles diverse activities in four Business Platforms: Metals and Recycling, Healthcare, Semiconductor and Electronics, as well as Industrials. Customers benefit from innovative technologies and solutions based on broad materials knowledge and technological leadership. In the 2023 financial year, the group generated revenues of €25.6 billion (US$27.7 billion*) with approximately 16,400 employees in 40 countries. Heraeus is one of the top 10 familyowned companies in Germany.

Inovedis stands for innovation in medical technology. As insiders, we know the issues that affect doctors and patients in everyday clinical practice. Our new innovation, SINEFIX™, came about because we wanted to improve the prevailing surgical method for refixation of the rotator cuff. And we have succeeded in doing that: For the first time, our PEEK implant creates a planar and stable connection between tendon and bone - and we assume that SINEFIX™ enables optimal healing. This saves time and money, for the doctors as well as their patients. In this way, we also position our products as an asset for the healthcare sector, which has to counter increasing cost pressure.

InspireMD is a commercial-stage medical device company with proprietary and innovative stent designs with integrated embolic prevention systems (EPS) designed for delivering neurovascular protection and stroke prevention. InspireMD is dedicated to the development of advanced technologies and seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for treatment of carotid artery disease by providing outstanding acute results and durable stroke free long-term outcomes through a proprietary stent platform, CGuard™ EPS. CGuard brings to the world the only carotid stent platform with patented MicroNet™ mesh technology designed to reduce stroke during and after CAS. InspireMD (NSPR) is traded on NASDQ Capital Markets.

Repairon's mission is the development, the manufacturing and the commercialization of induced pluripotent stem cell (iPSC) based tissues for organ repair. Our lead product are contractile heart tissue patches – Engineered Human Myocardium (EHM) – for the treatment of patients with advanced heart failure.

Founded in 2000, TauroPharm GmbH is a German company specialising in medical devices with antimicrobial efficacy. As TauroLock™ solutions have been recommended in expert guidelines, we continue to expand our global network.  Our mission  TauroPharm aims to make the application of vascular access devices (VAD) easier and safer. We are developing more effective ways to prevent catheter-associated complications – ranging from blood clotting to fatal infections. Improving the patient's quality of life remains our number-one priority.  Our products  We have created a range of lock solutions suitable for implanted central-venous catheters (CVC) and port systems. These products contain several ingredients to prevent catheter occlusion and catheter-related infections. Today, TauroLock™ solutions are recommended in interdisciplinary guidelines on a national and international scale. These include the ESPEN (European Society for Clinical Nutrition and Metabolism), GAVeCeLT (Italian association for long-term central-venous access devices), SFNCM (French Society of Clinical Nutrition and Metabolism), and DGfN (German Society of Nephrology). All TauroLock™ products have been investigated in clinical trials and are certified by regulatory bodies.  Our sales network  To distribute our products, we collaborate with international partners who provide support and advice to customers in their respective countries. Our correspondents have been carefully selected and hold trust-based partnerships with healthcare professionals in nephrology, oncology, gastroenterology, intensive and palliative medicine, and home care.   Our educational programmes  TauroPharm offers special training in all countries where TauroLock™ products are sold and implemented. These programmes help distributors familiarise themselves with our lock solutions and their application. Privacy policy: https://www.wonderlink.de/@tauropharm

TRiCares GmbH is a medical device company based in Munich, Germany, with additional offices in Paris, the U.S., and Brazil. Founded in 2013, the company specializes in minimally invasive solutions for tricuspid regurgitation (TR), a serious heart valve condition affecting millions of patients. TRiCares focuses on transcatheter tricuspid valve replacement (TTVR) systems, aiming to meet the clinical need for non-surgical treatments. The flagship product, Topaz, is a transfemoral TTVR system designed for easy implantation via the femoral vein. It features a dual-stent design that accommodates anatomical variability and is suitable for high-risk patients, avoiding the need for open-heart surgery. TRiCares is actively conducting clinical trials in the U.S., Canada, and Europe to further validate the effectiveness of the Topaz system. Recently, the company raised $50 million in Series D financing to support its clinical milestones and expand its market presence.